ClinicalTrials.gg

Program

duvelisib

Also written as “Duvelisib”, “IPI-145” and “IPI-145 (duvelisib)”.

Its studies are mostly in Leukemia, Lymphocytic, Chronic, B-Cell · Lymphoma · Lymphoma, Follicular · Hematologic Neoplasms · Mycosis Fungoides, led by 3 companies.

Furthest: phase 3, since Nov 13, 201326 company-led studies, 2 open or runningNext primary completion: Feb 2028 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
SecuraBio232 open or runningphase 3since Nov 13, 2013Nov 17, 2011Feb 2028phase 3 · NCT06522737
AbbVie20 open or runningphase 1since Oct 21, 2015Oct 21, 2015none ahead
CSPC Pharmaceutical Group10 open or runningphase 2since Apr 24, 2020Apr 24, 2020none ahead

Also a collaborator on its studies: Infinity Pharmaceuticals.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 11 studies since Nov 17, 2011.

  1. Jul 25, 2014Phase 3 study in Lymphoma, FollicularSecuraBio · NCT02204982 · 13 enrolled · Australia, France, Italy and more
  2. Nov 10, 20142 phase 1 studiesSecuraBio · NCT02292225, NCT02307461
  3. Oct 7, 2015Phase 3 study in Lymphoma, FollicularSecuraBio · NCT02576275 · United States
  4. Oct 21, 2015AbbVie's first study: phase 1 study in LymphomaNew to AbbVieAbbVie · NCT02598570 · 7 enrolled · Japan
  5. Nov 4, 2015Phase 2 study in LymphomaSecuraBio · NCT02605694 · United States
  6. Dec 23, 2015Phase 1 study in Leukemia, Lymphocytic, Chronic, B-CellAbbVie · NCT02640833 · United States
  7. Mar 15, 2016Phase 2 study in Hematologic NeoplasmsSecuraBio · NCT02711852 · 19 enrolled · United States, Italy
  8. Nov 29, 2017Phase 2 study in Leukemia, Lymphocytic, Chronic, B-CellSecuraBio · NCT03370185 · United States
  9. Dec 1, 2017Phase 2 study in Lymphoma, T-Cell, PeripheralSecuraBio · NCT03372057 · 156 enrolled · United States, Germany, Italy and more
  10. Jul 10, 2019Phase 2 study in Indolent Non-Hodgkin LymphomaSecuraBio · NCT04038359 · 103 enrolled · United States, Czechia, Germany and more
  11. Dec 4, 2019Phase 2 study in Squamous Cell Carcinoma of Head and NeckSecuraBio · NCT04193293 · 2 enrolled · United States
  12. Apr 24, 2020CSPC Pharmaceutical Group's first study: phase 2 study in Lymphoma, FollicularNew to CSPC Pharmaceutical GroupCSPC Pharmaceutical Group · NCT04707079 · 24 enrolled · China
  13. Jul 22, 2024Phase 3 study in LymphomaSecuraBio · NCT06522737 · 124 planned · Belgium, Czechia, Denmark and more
  14. Jul 15, 2026Phase 1 study in Mycosis FungoidesSecuraBio · NCT07714187 · 30 planned · United States

Ahead

  1. Feb 2028Primary completion: phase 3 study in LymphomaSecuraBio · NCT06522737
  2. Oct 2028Primary completion: phase 1 study in Mycosis FungoidesSecuraBio · NCT07714187

TargetBeta

“PI3-kinase p110-delta subunit inhibitor; PI3-kinase p110-gamma subunit inhibitor”ChEMBL 37, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
gedatolisibrulePfizerphase 39
paxalisibrulekazia-therapeutics-limitedphase 24

Studies

All 26 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07714187Mycosis Fungoides · United States1Not yet recruitingSecuraBioOct 202830
NCT06522737Lymphoma · Belgium, Czechia, Denmark and more3RecruitingSecuraBioFeb 2028124
NCT04707079Lymphoma, Follicular · China2UNKNOWNCSPC Pharmaceutical GroupOct 31, 202124
NCT04193293Squamous Cell Carcinoma of Head and Neck · United States2TerminatedSecuraBioDec 10, 20202
NCT04038359Indolent Non-Hodgkin Lymphoma · United States, Czechia, Germany and more2CompletedSecuraBioJul 24, 2023103
NCT03372057Lymphoma, T-Cell, Peripheral · United States, Germany, Italy and more2CompletedSecuraBioDec 22, 2023156
NCT03370185Leukemia, Lymphocytic, Chronic, B-Cell · United States2WithdrawnSecuraBioJun 20200
NCT02711852Hematologic Neoplasms · United States, Italy2CompletedSecuraBioMay 4, 202019
NCT02640833Leukemia, Lymphocytic, Chronic, B-Cell · United States1WithdrawnAbbVieJan 20200
NCT02605694Lymphoma · United States2WithdrawnSecuraBioNov 20160
NCT02598570Lymphoma · Japan1CompletedAbbVieDec 20167
NCT02576275Lymphoma, Follicular · United States3WithdrawnSecuraBioNov 20160
NCT02307461Healthy · United States1CompletedSecuraBioAug 2015103
NCT02292225Leukemia, Lymphocytic, Chronic, B-Cell · United States, Canada1TerminatedSecuraBioNov 20163
NCT02204982Lymphoma, Follicular · Australia, France, Italy and more3TerminatedSecuraBioDec 201613
NCT02095587Hepatic Impairment · United States1CompletedSecuraBioJul 201424
NCT02049515Leukemia, Lymphocytic, Chronic, B-Cell · United States, Australia, Austria and more3CompletedSecuraBioJun 12, 202099
NCT02004522Leukemia, Lymphocytic, Chronic, B-Cell · United States, Australia, Austria and more3CompletedSecuraBioMay 19, 2017319
NCT01947777Healthy · United States1CompletedSecuraBioNov 201314
NCT01925911Healthy · United States1CompletedSecuraBioSep 201314
NCT01882803Indolent Non-Hodgkin Lymphoma · United States, Belarus, Belgium and more2CompletedSecuraBioNov 18, 2020129
NCT01851707Arthritis, Rheumatoid · Bulgaria, Colombia, Germany and more2CompletedSecuraBioDec 2014322
NCT01836861Healthy · Netherlands1CompletedSecuraBioApr 20136
NCT01653756Asthma · Germany, United Kingdom2CompletedSecuraBioAug 201450
NCT01549106Healthy Volunteers · Netherlands1CompletedSecuraBioFeb 2012106
NCT01476657Hematologic Neoplasms · United States1TerminatedSecuraBioDec 2016210

How it is read

Names in the registry

  • “Duvelisib”, 16 entries
  • “IPI-145”, 9 entries
  • “IPI-145 (duvelisib)”, 3 entries
  • “IPI-145, a PI3K Inhibitor”, 1 entry
  • “duvelisib”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.